Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
American Journal of Hematology
|
May 9, 2012
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents
Anna Tasidou, Maria Roussou, Evangelos Terpos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 10, 2011
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma
Maria Gkotzamanidou, Efstathios Kastritis, Maria Roussou Magdalini Migkou Maria Gavriatopoulou, et al.
International Journal of Cancer
|
November 5, 2011
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy
Evangelos Terpos, Dimitrios Christoulas, Eirini Katodritou, et al.
British Journal of Clinical Pharmacology
|
March 22, 2012
Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs
Dimitra T Stefanou, Hara Episkopou, Soterios A Kyrtopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 4, 2015
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma
Gerasimos-Petros Papassotiriou, Efstathios Kastritis, Maria Gkotzamanidou, et al.
American Journal of Hematology
|
August 29, 2013
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group
Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, et al.
American Journal of Hematology
|
May 30, 2012
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients
Lia A Moulopoulos, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Cancers
|
January 20, 2021
Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Panagiota Economopoulou, Maria Anastasiou, George Papaxoinis, et al.
ESMO Open
|
May 17, 2020
Prognostic impact of indoleamine 2,3-dioxygenase 1 <i>(IDO1)</i> mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma
Panagiota Economopoulou, Athina Kladi-Skandali, Areti Strati, et al.
Oral Oncology
|
June 11, 2019
Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC)
Panagiota Economopoulou, George Koutsodontis, Areti Strati, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
American Journal of Hematology
|
May 9, 2012
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents
Anna Tasidou, Maria Roussou, Evangelos Terpos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 10, 2011
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma
Maria Gkotzamanidou, Efstathios Kastritis, Maria Roussou Magdalini Migkou Maria Gavriatopoulou, et al.
International Journal of Cancer
|
November 5, 2011
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy
Evangelos Terpos, Dimitrios Christoulas, Eirini Katodritou, et al.
British Journal of Clinical Pharmacology
|
March 22, 2012
Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs
Dimitra T Stefanou, Hara Episkopou, Soterios A Kyrtopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 4, 2015
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma
Gerasimos-Petros Papassotiriou, Efstathios Kastritis, Maria Gkotzamanidou, et al.
American Journal of Hematology
|
August 29, 2013
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group
Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, et al.
American Journal of Hematology
|
May 30, 2012
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients
Lia A Moulopoulos, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Cancers
|
January 20, 2021
Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Panagiota Economopoulou, Maria Anastasiou, George Papaxoinis, et al.
ESMO Open
|
May 17, 2020
Prognostic impact of indoleamine 2,3-dioxygenase 1 <i>(IDO1)</i> mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma
Panagiota Economopoulou, Athina Kladi-Skandali, Areti Strati, et al.
Oral Oncology
|
June 11, 2019
Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC)
Panagiota Economopoulou, George Koutsodontis, Areti Strati, et al.
Page
of 3